BXTA is on a mission to educate the world on the benefits of LATP prostate biopsy: transperineal biopsies carried out under local anaesthetic.

As the sole distributor, outside North America, for the PrecisionPoint™ single use device, that enables LATP, and alongside international partners that including organisations such as the British Association of Urological Surgeons, The Royal Society of Medicine, Prostate Cancer UK, The British Association of Urological Nurses and many others, we are committed to eradicating the current ‘de facto’ standard method for prostate cancer diagnosis: the transrectal ultrasound (TRUS) guided or transrectal biopsy.

Yet, TRUS biopsy has a high risk of sepsis / serious infection and bleeding, as well as inaccurate identification of potential cancer cells. The alternative transperineal or template (TP) biopsy has, in the past, typically only been available to men at greater risk of infection from certain medical conditions, and had to be done under general anaesthetic because of the need for multiple biopsy punctures

The PrecisionPoint™ Transperineal Access System is now revolutionising the methodology for obtaining prostate biopsies. Not only does it take full advantage of the transperineal path, decreasing risk of infections, it allows for more thorough sampling of all regions of the prostate including those difficult to access with the transrectal approach. 

PrecisionPoint™ provides improved accuracy and convenience, enabling surgeons to achieve savings in both costs and time. The transperineal biopsy technique is free hand, therefore the practitioner can easily target the desired locations with certainty and through a single puncture of the skin, allowing the procedure to be conducted under local anaesthetic in an outpatient setting.

• Convenient freehand, easy to learn
• Decreases risk of sepsis over the transrectal approach, removing the necessity for routine antibiotic use thereby decreasing the risks of the spread of antibiotic-resistant microorganisms.
• Allows systematic template-style sampling without the need for a template or stepper and stabilizer unit
• Higher & more accurate cancer detection rate than TRUS
• Performed under local anaesthesia, so the procedure can be undertaken in an outpatient clinic

By passing the biopsy needle through the perineum instead of the rectum, the risks associated with the transrectal approach are avoided. The practitioner is not restricted to biopsy locations dictated by a grid configuration, since the technique is freehand. The practitioner can freely manoeuvre the ultrasound probe to align the access needle to target the desired locations with certainty for targeted and systematic biopsies.

This low cost disposable device represents a safer and more accurate method for urologists to detect potential incidents of prostate cancer at an earlier stage of progression, through its ability to systematically allow access to the whole gland.

BXTA is working with leading urologists, clinical nurse specialists and thought leaders in the field of prostate cancer diagnosis to eradicate TRUS biopsy, in favour of LATP as the new standard of care.

We have established regional centres of clinical excellence across Europe, Australia and New Zealand, as part of an international training programme designed to increase the number of consultants, registrars and clinical nurse specialists skilled in this new advanced prostate biopsy technique.